Results 191 to 200 of about 326,443 (336)

Non-small cell lung cancer: HER2 oncogene status

, 2015
D. S. Kobyakov, A. M Avdalyan, В. В. Климачев, А. Ф. Лазарев, Е. Л. Лушникова, L M Nepomnyaschikh   +5 more
openalex   +1 more source

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population [PDF]

, 2012
Hasan Körkaya, Gwang-il Kim, April Davis, Fayaz Malik, N. Lynn Henry, Suthinee Ithimakin, Ahmed A. Quraishi, Nader Tawakkol, Rosemarie C. D'Angelo, Amanda K. Paulson, Susan Chung, Tahra Luther, Hayley J. Paholak, Suling Liu, Khaled A. Hassan, Qin Zen, Shawn G. Clouthier, Max S. Wicha   +17 more
openalex   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV. [PDF]

PLoS One
Liu C, Ren Y, Luo X, Zhou P, Du X, Wang Q, Han X, Xu Y, Wang P, Zhao D, Yang H.   +10 more
europepmc   +1 more source

A Long-surviving（5 Years）Patient with HER2-positive/AFP-producing/Unresectable Advanced Gastric Cancer following Multidisciplinary Treatment

, 2017
Toshihiro Inokuchi, Atsushi SEYAMA, Yuki Suehiro, Atsushi Suga, Takashi Inoue, Tomoaki MORITA   +5 more
openalex   +2 more sources

High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis

, 2021
Madhumathy G Nair, Jyothi S. Prabhu, Sridhar TS   +2 more
openalex   +1 more source

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study. [PDF]

MedComm (2020)
Huang J, Wang H, Tong Y, Hong J, Zhu Y, Ren W, Yu J, Shi H, Gao W, Zhu S, Wu J, Huang O, Li J, He J, Chen W, Li Y, Shen K, Chen X.   +17 more
europepmc   +1 more source

Evaluation of hormone receptors status (estrogen & progesterone) and human epidermal growth factor receptor R-2 (HER2) in breast cancer in Basrah

, 2012
Ahmed H. Ali Al-Ahmed, Noor S. Jumaah
openalex   +1 more source

Development of tCAP(N3): Affinity Peptide‐Aided, pH‐Triggered Strategy for Site‐Specific Native IgG Modification

Chemistry – A European Journal, EarlyView.
The tCAP(N3) reagent, featuring a stable and self‐activating precursor, enables site‐specific conjugation of native IgGs. This Fc‐affinity peptide approach selectively transfers an Ac‐Lys(N3)‐Gly‐Gly payload to Lys248, producing divalently azidated antibody while preserving its biological function.
Hiroko Kawakami, Abdur Rafique, Shugo Tsuda, Asaki Nagashima, Yukie Nohara, Naoki Dozono, Ken Sakamoto, Shun Masuda, Masato Kiyoshi, Hiroko Shibata, Akiko Ishii‐Watabe, Taku Yoshiya, Yuji Ito   +12 more
wiley   +1 more source

Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. [PDF]

Clin Cancer Res
Adesoye T, Dumbrava EE, Raghav KPS, Sahin AA, Chen H, Lee SS, Javle MM, Pant S, Alhalabi O, Le X, Valero V, Pohlmann PR, Meric-Bernstam F.   +12 more
europepmc   +1 more source